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Objectives: We have previously demonstrated an importance of endothelin-1 in
diabetic patients undergoing bypass surgery. Recent evidence suggests that cardi-
omyocytes might also produce endothelin-1, which might directly impair myocyte
contractility by increasing intracellular calcium levels. Because hyperglycemia is a
potent stimulus of endothelin-1 production, we hypothesized that increased produc-
tion, action, or both of endothelin-1 might be a mediator of direct cardiomyocyte
injury in diabetes. Therefore we studied the effects of endothelin receptor blockers
(BQ-123 and bosentan) on hyperglycemia-induced endothelin-1 production and
cellular injury after ischemia-reperfusion.
Methods: Using a human ventricular heart cell model of simulated ischemia-
reperfusion, we studied the effects of normoglycemia (5 mmol/L, 48 hours) and
hyperglycemia (25 mmol/L, 48 hours) on cellular injury and endothelin-1 produc-
tion. Furthermore, the effects of selective endothelin-A and mixed endothelin-A/B
receptor antagonism (with BQ-123 and bosentan, respectively) were evaluated.
Results: Cellular injury, as assessed by means of trypan blue uptake, was higher in
human ventricular heart cells subjected to hyperglycemia and simulated ischemia-
reperfusion injury (P  .01); this effect was prevented with both BQ-123 and
bosentan (P .01). In addition, heart cells from the hyperglycemic group elaborated
more endothelin-1 after ischemia-reperfusion (P  .02).
Conclusions: Endothelin-1 production and cellular injury were greater in human
ventricular heart cells subjected to hyperglycemic conditions and simulated is-
chemia-reperfusion. These effects are mediated by endothelin-A receptors because
both BQ-123 and bosentan exerted similar degrees of protection. Endothelin recep-
tor blockade is a novel strategy to improve the resistance of the diabetic heart to
cardioplegic arrest and reperfusion.
We have previously demonstrated an important vasoconstrict-ing response mediated by endothelin-1 (ET-1) during reper-fusion injury in diabetes.1 In this study the coronary effluentrelease of ET-1 was higher in diabetic than in nondiabeticpatients after cardiopulmonary bypass (CPB) and reperfu-sion. Furthermore, diabetic coronary microvessels re-
sponded to CPB and reperfusion with greater ET-1-mediated vasoconstriction and
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diminished nitric oxide-mediated vasodilatation; these ef-
fects were attenuated by ET antagonism.1
Recent evidence suggests that cardiomyocytes (in addi-
tion to endothelial cells) might also produce ET-1, which
might directly impair myocyte contractility by increasing
intracellular calcium levels.2 In the present study we hy-
pothesized that hyperglycemia directly impairs cardiomyo-
cyte survival through the production of ET-1. To this aim,
we examined the effects of ET receptor blockade (with
BQ-123 and bosentan) on ET-1 production and cellular
injury in human cardiomyocytes subjected to simulated
ischemia-reperfusion in hyperglycemic compared with nor-
moglycemic environments.
Patients and Methods
Human Heart Cell Model of Ischemia-Reperfusion
Our method of culturing heart cells from human ventricular biopsy
specimens has been previously described in detail.3-5 In brief, 5- to
20-mg biopsy specimens were obtained from the right ventricular
outflow tracts of patients undergoing elective surgery for tetralogy
of Fallot. After digestion with trypsin (0.2%) and collagenase
(0.1%), the separated cells were seeded onto cell-culture dishes
and cultured at 37°C in a 5% carbon dioxide atmosphere in
Iscove’s modified Dulbecco’s medium with 10% fetal bovine
serum, 100 U/mL penicillin, 100 g/mL streptomycin, and 0.1
mmol/L -mercapthoethanol. Cells were cultured under either
hyperglycemic (25 mmol/L) or normoglycemic (5 mmol/L) con-
ditions for 48 hours. Purification was achieved by using a dilution
cloning technique. Enzymatically isolated cells were seeded at a
low density to enable morphologic identification of individual
cardiomyocytes and separation from contaminating cell types.
Single cardiomyocyte colonies were then transferred to a separate
culture dish. The use of cardiomyocytes facilitates examining the
effects of ischemia-reperfusion independent of other cell types,
such as endothelial cells or fibroblasts. Our technique of simulated
ischemia-reperfusion has also been described in detail previous-
ly.3,4 In brief, after 30 minutes of stabilization in 10 mL of
normoxic phosphate-buffered saline solution (PBS), ischemia was
simulated by exposing the cells to a low volume (1.6 mL) of
anoxic PBS at 37°C for 90 minutes. During this period, the cells
were placed in an airtight Plexiglas chamber, which was continu-
ously flushed with 100% nitrogen to maintain anoxic conditions.
Ischemia was followed by a reperfusion period in which the cells
were exposed to 10 mL of normoxic PBS at 37°C for 30 minutes.
Both low volume and anoxic conditions were used to mimic
ischemia. The volume of anoxic perfusate used (1.6 mL) was the
minimum volume required to coat the cellular monolayer for the
prevention of cellular dehydration during the ischemic period. To
verify the presence of anoxia, we placed 2 mL of anoxic PBS in a
center dish within the sealed chamber and tested at the termination
of each ischemic period to ensure a PO2 of 0 mm Hg. Anoxic PBS
was prepared by bubbling with 5% carbon dioxide and 95%
nitrogen that had first been passed through an oxygen trap (1%
wt/vol NaHSO3 in deionized water). The solution (monitored with
a blood gas analyzer) was degassed until a measured PO2 of 0 mm
Hg was achieved. The pH was adjusted to 7.4  0.05, and an
osmolality of 290  20 mOsm/L was ensured before use. For the
assessment of cellular injury, cells were stained with trypan blue at
the end of the reperfusion period (ie, after 150 minutes of incuba-
tion for the nonischemic groups). Injured cells were unable to
exclude the large-molecular-weight dye and stained blue. The
above protocol was repeated in the presence of BQ-123 (ETA
receptor blocker, 1 mol/L) and bosentan (ETA/B receptor blocker,
100 mol/L; Actelion Ltd) added before reperfusion. A single
blinded observer performed cell counts. In addition, we measured
ET-1 production from human heart cells after ischemia-reperfu-
sion in the hyperglycemic and normoglycemic conditions. Heart
cells were lysed with NP40, after which a commercial enzyme
immunoassay kit was used to assess ET-1 production (American
Research Products, Inc).
Statistical Analysis
Data are presented as means  SEM. Data were compared with a
2-way analysis of variance. When the F ratio indicated a significant
effect, differences were specified by using a Newman-Keuls test
for post hoc comparisons.
Results
Effects of Hyperglycemia Versus Normoglycemia on
Human Heart Cell Injury
Figure 1 depicts the effects on cellular injury of culturing
human ventricular heart cells with either 5 or 25 mmol/L
glucose for 48 hours, as assessed with trypan blue exclu-
sion. Heart cells subjected to simulated anoxia and reoxy-
genation exhibited greater cellular injury (cell survival of
52%  4% vs 28%  3% for normoglycemic conditions, P
 .01). Importantly, this effect was prevented by the ETA
specific antagonist BQ-123 and the mixed ETA/B antagonist
bosentan (when administered before reperfusion, Figure 1).
ET blockade did not affect cell survival in the nonischemic
group (cell survival of nonischemic  bosentan [normogly-
cemia] group of 22%  3% vs 17%  4% for nonischemic
group; P  .33; cell survival of nonischemic  bosentan
[hyperglycemia] group of 18%  4% vs 20%  3% for
nonischemic group; P  .40).
Hyperglycemia Exaggerates ET-1 Production
The effects of simulated hyperglycemia on ET-1 production
were studied. Hyperglycemic heart cells produced greater
amounts of ET-1 after simulated ischemia-reperfusion when
compared with those in the normoglycemic group (418 
45 vs 303  23 in the normoglycemic group, P  .02;
Figure 2).
Discussion
We hypothesized that hyperglycemia might stimulate heart
cells to produce ET-1, which might increase cell injury after
simulated ischemia-reperfusion. Our data demonstrate that
human ventricular heart cells subjected to 48 hours of
hyperglycemia elaborated more ET-1 and had less cell
survival. Furthermore, BQ-123 and bosentan prevent hyper-
glycemia-induced cell injury when used before reperfusion.
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These data suggest, for the first time, an effect of ET-1 on
human heart cell injury independent of other cell types, such
as endothelial cells, platelets, or neutrophils. Dorman et al2
have demonstrated that myocyte ET-1 exposure during car-
dioplegic arrest exacerbates contractile dysfunction after
reperfusion by mean of alterations in intracellular calcium
homeostasis and a reduction in -adrenoceptor responsive-
ness, a phenomenon that frequently occurs after cardiac
operations. Hyperglycemia in diabetic patients might impair
contractility through these mechanisms. We have previ-
ously demonstrated that diabetes is an independent predictor
of low output syndrome after coronary artery bypass graft-
ing,6 and hence it is tempting to speculate that increased
myocyte ET-1 production might be an important contributor
to this phenomenon.
Our model of ischemia-reperfusion does not completely
reproduce the in vivo responses. The heart cells used in
these studies have been extensively evaluated in previous
reports. These myocytes retain many characteristics of
freshly isolated cells but have distinct differences. These
cells become quiescent after enzymatic digestion and pas-
saging. Despite an abundant supply of mitochondria and
Figure 1. Cellular injury (assessed by means of trypan blue uptake) in human ventricular heart cells subjected to
simulated ischemia-reperfusion. Cells subjected to 48 hours of hyperglycemia exhibited increased cellular
damage. This response was prevented by BQ-123 (an ETA antagonist) and bosentan (an ETA/B antagonist). *P  .01
versus normoglycemic group and hyperglycemic group plus BQ-123 and hyperglycemic group plus bosentan.
Figure 2. Effects of normoglycemia versus hyperglycemia on human heart cell ET-1 production. Hyperglycemic
heart cells elaborate more ET-1 after ischemia-reperfusion when compared with those in the normoglycemic
group. *P  .02 versus normoglycemic group.
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contractile proteins, the sarcomeres become disrupted dur-
ing division and do not reestablish their characteristic func-
tional format. However, the metabolic response of these
cells after ischemia is similar to our intraoperative findings
during cardiac operations.7-9 Furthermore, the cellular con-
centrations of troponin I, troponin T, and creatine kinase
MB isoform are similar to those seen in vivo. Although the
molecular and biochemical characteristics of these cells
resemble in vivo cardiomyocytes, these cells undergo phe-
notypic changes, become quiescent, and regain their ability
to divide. Therefore these cells retain many characteristics
of normal human myocardium and might simulate the hu-
man heart during cardioplegic arrest. The heart cells in
culture are easily differentiated from other cell types. En-
dothelial cells are oval (15  20 mm) and fibroblasts are
spindle-shaped (4  80 mm) compared with the rectangular
and much larger heart cells (40  80 mm). In addition,
endothelial cells grow poorly in the medium used for heart
cells, whereas fibroblasts have a much faster doubling time
in culture and are easily identified as a spindle-shaped
contaminant. Our model of ischemia-reperfusion is similar
to the effects of global ischemia on the myocardium. Al-
though the volume overlying our cells during ischemia
exceeds the volume of fluid surrounding cardiomyocytes in
the globally ischemic heart, the reduction of the volume of
ischemic PBS from 10 to 1.5 mL resulted in a marked
increase in the products of ischemic metabolism (lactate), a
decrease in extracellular pH, and progressive cell injury.
Thus our model simulates low-flow ischemia analogous to
limited cardioplegic perfusion during cardiac operations.
The addition of glucose to cardioplegic solutions was
demonstrated to be detrimental if the products of anaerobic
metabolism (lactate acidosis) were not washed from the
heart with repeated cardioplegic infusions. Because acidosis
might increase ET-1 production, the detrimental effects of
glucose might be due to excessive ET-1 production.
Clinical Perspective
There is a growing body of evidence to suggest that ET-1
might represent an important mediator of perioperative in-
jury during cardiac operations.10-15 Elegant studies by Bond
et al10 and Ergul et al15 have suggested that exaggerated
ET-1 production during CPB is closely associated with
indices of postoperative recovery, including prolonged in-
tensive care unit stay, ventilation times, and inotropic sup-
port. Furthermore, exaggerated ET-1 production during car-
diac operations might represent an important mediator of
perioperative vasospasm in conduits used for bypass graft-
ing.15 In addition, increased production of ET-1 by the heart
and pulmonary circulation might be one of the key deter-
minants of increased pulmonary arterial pressure noted
postoperatively.10-15 Importantly, antagonism of ET-1 ac-
tion with potent ET receptor antagonists has been demon-
strated to prevent CPB-induced increases in pulmonary
vascular resistance.12 The work presented in our articles
extends this body of evidence and suggests that the diabetic
milieu exaggerates the deleterious effects of ET-1 on vas-
cular reactivity and myocyte survival. Given the increasing
understanding of the role of ET-1 in cardiac surgery, it is
reasonable to suggest that a phase I study be conducted to
develop the use of ET receptor antagonists, such as bosen-
tan, for myocardial protection in high-risk patients under-
going cardiac surgery.
Conclusion
ET-1 production and cellular injury was amplified when
human ventricular heart cells were subjected to hypergly-
cemia before simulated ischemia-reperfusion. However,
both ET-1 production and cell death were reduced by means
of treatment with BQ-123 and bosentan before reperfusion.
These observations, in conjunction with those made in our
previous publication,1 suggest that antagonism of ET recep-
tors might decrease endothelial dysfunction and reduce car-
diomyocyte death in diabetes and hyperglycemic condi-
tions. Diabetic hyperglycemia might exacerbate reperfusion
injury in ischemic regions being revascularized, and bosen-
tan might represent a novel therapy for the cardiovascular
complications of diabetes.16,17
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Discussion
Dr Alain Carpentier (Paris, France). I enjoyed your presen-
tation very much. I think it is a very important one. I would like to
ask you one question. You are talking about cardioplegia. As you
know, there are different sorts of cardioplegia, particularly blood
cardioplegia and crystalloid cardioplegia. Have you investigated
whether these might have some effect and whether it is the car-
dioplegic arrest or the type of substance used to carry out cardio-
plegia that might have an influence?
Dr Verma. Thank you very much for your comments.
This was a small study, and all of our patients were subjected
to one particular type of cardioplegia, blood cardioplegia. We have
not compared that with crystalloid cardioplegia. I do believe that
Dr Sellke’s group has demonstrated some very nice differences
between crystalloid cardioplegia and blood cardioplegia in terms
of atrial microvessel and endothelial function. But this certainly
needs to be followed up, and I thank you for your question.
Dr Jakob Vinten-Johansen (Atlanta, Ga). That was a very
nice study, and I think future studies certainly will point toward ET
as a contributor to ischemia-reperfusion injury.
Do you think that the effects of ET are simply acting in
opposition to nitric oxide in terms of its vasoreactivity responses,
or is it actually playing an active role in initiating and promulgat-
ing the reperfusion injury response? For example, does it stimulate
the release of proinflammatory mediators, does it stimulate the
upregulation of adhesion molecules, or does it stimulate neutro-
phils themselves?
Dr Verma. You bring up an interesting point. First, you high-
light one of the limitations of the study, and that is that we have not
provided an index of nitric oxide production. Therefore it is hard
to understand what the regulation between ET and nitric oxide is
in this model. However, there are recent studies by Dr Sharma’s
group that demonstrate that diabetic patients might elaborate
greater amounts of ET in the face of normal nitric oxide produc-
tion.
Your question about the other effects of ET and how it might
relate to the tenets of ischemia-reperfusion is also an important
one. We do not have evidence on other mechanisms; however, ET
has now been implicated as an important mediator of P-selectin-
dependent neutrophil rolling and later firm adhesion of the neu-
trophils.
Professor Magdi Yacoub (London, United Kingdom). I have 2
questions. One is that you have shown hyperreactivity to ET.
Would you like to speculate or have you investigated why that is?
Is it increased numbers of receptors?
The second question is, ET is not all bad news, as you know,
because it is a compensatory thing, and it has an inotropic effect.
Therefore would you like to tell us why is it that the body is doing
this in the first place in diabetes? Is it trying to do something that
you are trying to block?
Dr Verma. Thank you for your comments, Professor Yacoub.
In response to your first question, the fact that the responsiveness
to ET in the microvasculature is enhanced, what are the subcellular
mechanisms mediating that effect? When you think of this, the first
thing that would come to mind is, are the ET receptor densities
different? In diabetic experimental models, ET receptor density
remains the same. Therefore it is probably an event that is below
the ET receptors and might involve greater sensitivity of the
myofibrils to the effects of ET.
Now, in response to your second question—this homeostatic
mechanism—as to why ET goes up, is it a compensation? ET, as
you mentioned, might be a compensatory positive inotrope. That
appears to not be true in diabetic experimental models of heart
failure. The positive inotropic effects of ET might occur in a
noncardiomyopathic or a noncongestive heart failure type of
model as opposed to a failing heart.
I thank you very much for your comments.
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